Gabapentin in dermatology

Dermatology

Volumn 211, Issue 2, 2005, Pages 79-80

  Misery, Laurent ^a  

^a CHU MORVAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; BARBITURIC ACID DERIVATIVE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CARBAMAZEPINE; CEFTRIAXONE; GABAPENTIN; LAMOTRIGINE; MONOAMINE; PHENYTOIN; TRICYCLIC ANTIDEPRESSANT AGENT; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ANALGESIA; ASTHENIA; ATAXIA; BORRELIA INFECTION; CALCIUM CONDUCTANCE; COMPLEX REGIONAL PAIN SYNDROME TYPE I; DIPLOPIA; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; EDITORIAL; EPILEPSY; ERYTHROMELALGIA; GLOSSODYNIA; HEADACHE; HUMAN; LIPOPHILICITY; MYOCLONUS; NAUSEA; NERVE EXCITABILITY; NEUROPATHIC PAIN; NONHUMAN; PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRURITUS; RHINITIS; SKIN DISEASE; SKIN MANIFESTATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TREMOR; VULVODYNIA;

AMINES; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LYME NEUROBORRELIOSIS; MALE; NEURALGIA; PAIN MEASUREMENT; PILOT PROJECTS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 23844433031     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086432     Document Type: Editorial

References (14)

1. Magnus L: Nonepileptic uses of gabapentin. Epilepsia 1999;40:S66-S72.
2. Rogawski MA, Loscher W: The neurobiology of antiepileptic drugs for the treatment of non-epileptic conditions. Nat Med 2004;10:685-692.
3. Spina E, Perugi G: Antiepileptic drugs: Indications other than epilepsy. Epileptic Disord 2004;6:57-75.
4. Tennyson H, Levine N: Neurotropic and psychotropic drugs in dermatology. Dermatol Clin 2001;19:179-197.
5. Taylor CP, Gee NS, Su TZ, et al: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233-249.
6. Nicholson B: Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000;101:359-371.
7. De Toledo JC, Minagar A, Lowe MR, et al: Skin eruption with gabapentin in a patient with repeated AED-induced Stevens-Johnson syndrome. Ther Drug Monit 1999;21:137-138.
8. Gomez-Criado MS, Ayani I, Leon-Colombo T, et al: Stevens-Johnson syndrome, toxic epidermal necrolysis and phenytoin: Factors linked to a higher risk. Rev Neurol 2004;38:1056-1060.
9. Argoff CE, Katz N, Backonja M: Treatment of postherpetic neuralgia: A review of therapeutic options. J Pain Symptom Manage 2004;28:396-411.
10. Plaghki L, Adriaensen H, Morlion B, et al: Systematic overview of the pharmacological management of postherpetic neuralgia. An evaluation of the clinical value of critically selected drug treatments based on efficacy and safety outcomes from randomized controlled studies. Dermatology 2004;208:206-216.
11. Scheinfeld N: The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol 2003;42:491-495.
12. Gustorff B, Hoechtl K, Sycha T, et al: The effects of remifentanil and gabapentin on hyperalgesia in a new extended inflammatory skin pain model in healthy volunteers. Anesth Analg 2004;98:401-407.
13. Weissenbacher S, Ring J, Hofmann H: Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage Lyme borreliosis: A pilot study. Dermatology 2005;211:123-127.
14. Dworkin RH, Backonja M, Rowbotham M, et al: Advances in neuropathic pain: Diagnosis, mechanisms and treatment recommendations. Arch Neurol 2003;60:1524-1534.